Catapult Therapeutics

Executive Summary

Catapult Therapeutics is a clinical-stage biopharmaceutical company developing CAP-100, a first-in-class anti-CCR7 monoclonal antibody targeting the underlying pathology of hematological malignancies. CCR7 is overexpressed in various B-cell and T-cell malignancies and plays a critical role in tumor cell homing, survival, and immune evasion. CAP-100 is designed to block CCR7 signaling, thereby disrupting these processes and potentially enhancing anti-tumor immune responses. The company is currently advancing CAP-100 through Phase 1 clinical trials in patients with relapsed/refractory hematological cancers. Initial data from this study, expected in the coming quarters, will be pivotal in demonstrating safety and preliminary efficacy. Catapult was founded in 2015 based on research from Hospital La Princesa in Madrid and is a privately held joint venture between Spanish and Dutch partners. As a small biotech operating in a competitive space, the company's success hinges on positive clinical data and securing additional funding or partnerships to continue development.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 dose-escalation data readout for CAP-100 in hematological malignancies80% success
• Q3 2026Presentation of preclinical data supporting CAP-100 in solid tumors or combination therapy70% success
• Q1 2027Announcement of partnership or licensing deal for CAP-10030% success